CD19 and hematopoietic and lymphoid system neoplasm: CAR T cell therapy has shown promising results for the treatment of blood cancers, particularly CD19 positive B cell malignancies with three products, Tisagenlecleucel (Kymriah) [5,6], Axicabtagene ciloleucel (Yescarta) [7,8] and most recently Brexucabtagene Autoleucel (Tecartus) [9,10] obtaining market authorisation.